12406 HORESHAM STREET, CARMEL, IN
Investor Presentation
Material disclosure
Reports First Quarter 2026 Financial Results and Corporate Highlights
Annual Report to Security Holders
Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences Enters Lease Agreement for New Office Space in Burlington, MA
Q1
FY 2025
Q3
Q2
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
S-1MEF